Neurology, Department of

Medicine & Life Sciences

1. Migraine Disorders 100%
2. Multiple Sclerosis 84%
3. Headache 60%
4. Alzheimer Disease 39%
5. Dementia 38%
6. Brain 37%
7. Stroke 31%
8. Therapeutics 26%
9. Tension-Type Headache 24%
10. Muscles 24%
11. Cerebrospinal Fluid 23%
12. Denmark 23%
13. Placebos 23%
14. Calcitonin Gene-Related Peptide 23%
15. Cluster Headache 22%
16. Cerebrovascular Circulation 21%
17. Systematic Reviews 21%
18. Biomarkers 21%
19. Cognitive Dysfunction 21%
20. Magnetic Resonance Imaging 20%
21. Positron-Emission Tomography 19%
22. Traumatic Brain Injury 19%
23. Receptor, Serotonin, 5-HT2A 19%
24. Headache Disorders 18%
25. Epilepsy 18%
26. Exercise 17%
27. Secondary Headache Disorders 17%
28. Population 17%
29. Mutation 17%
30. Healthy Volunteers 16%
31. Serotonin 16%
32. Cohort Studies 15%
33. Migraine with Aura 15%
34. White Matter 15%
35. Genes 15%
36. Relapsing-Remitting Multiple Sclerosis 15%
37. Depression 14%
38. Pain 14%
39. Migraine without Aura 13%
40. Pharmaceutical Preparations 13%
41. Glycogen Storage Disease Type V 13%
42. Frontotemporal Dementia 13%
43. Memory 13%
44. Cognition 12%
45. Neuroimaging 12%
46. Phenotype 12%
47. erenumab 11%
48. Pseudotumor Cerebri 11%
49. Single-Photon Emission-Computed Tomography 11%
50. Optic Neuritis 11%
51. Randomized Controlled Trials 11%
52. Meta-Analysis 11%
53. Sumatriptan 10%
54. Global Burden of Disease 10%
55. Natalizumab 10%
56. Huntington Disease 10%
57. Pituitary Adenylate Cyclase-Activating Polypeptide 9%
58. Safety 9%
59. Registries 9%
60. Guidelines 9%
61. Confidence Intervals 9%
62. Electroencephalography 9%
63. Serotonin Plasma Membrane Transport Proteins 9%
64. Elderly 8%
65. Leukoaraiosis 8%
66. Incidence 8%
67. Genome-Wide Association Study 8%
68. Interferon-beta 8%
69. Pharmacology 8%
70. Schizophrenia 8%
71. Intracranial Pressure 8%
72. Bipolar Disorder 8%
73. Hippocampus 8%
74. Prefrontal Cortex 8%
75. Brain Injuries 8%
76. Prospective Studies 7%
77. Induced Pluripotent Stem Cells 7%
78. Receptors, Serotonin, 5-HT4 7%
79. Cimbi-36 7%
80. Mortality 7%
81. Mitochondrial Myopathies 7%
82. Disability Studies 7%
83. Muscular Diseases 7%
84. Proteins 7%
85. Amyloid 7%
86. Tryptamines 7%
87. Antibodies 7%
88. Atrophy 7%
89. Neurons 7%
90. Major Depressive Disorder 7%
91. Gray Matter 7%
92. Neurodegenerative Diseases 7%
93. Nitroglycerin 7%
94. Regional Blood Flow 7%
95. Mitochondrial DNA 7%
96. Limb-Girdle Muscular Dystrophies 6%
97. Psychiatry 6%
98. Diabetic Nephropathies 6%
99. Quality of Life 6%
100. Seizures 6%